Hester Biosciences Receives Manufacturing License for H9N2 Avian Influenza Vaccine
Hester Biosciences has received a manufacturing license from the Food & Drugs Control Administration for its Low Pathogenic Avian Influenza (H9N2) vaccine for poultry. The H9N2 strain is a persistent challenge in the poultry industry, causing significant economic losses through reduced egg production and broiler performance. This vaccine was developed using technology acquired from ICAR-NIHSAD via Agrinnovate India. This regulatory milestone strengthens Hester's poultry healthcare portfolio and addresses a year-round comorbidity issue in the sector.
முக்கிய அம்சங்கள்
Received manufacturing and marketing license from FDCA for Inactivated Avian Influenza H9N2 vaccine.
Technology for the vaccine was acquired from ICAR-NIHSAD through Agrinnovate India.
Targets the H9N2 strain which causes significant economic losses in both layer and broiler poultry segments.
The vaccine aims to prevent irreversible drops in egg production and high mortality rates associated with the virus.
Strengthens the company's prevention-led poultry healthcare product pipeline.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that expands Hester's product offerings in the animal healthcare market. Monitor the commercial launch timeline and the subsequent impact on the poultry segment's revenue growth.
